#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Colorectal cancer metastatic Obesity Prostate cancer Crohn's disease Colorectal cancer Ovarian cancer Dementia Alzheimer's type Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Asthma Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Necrotising enterocolitis neonatal Malignant oligodendroglioma Hypertriglyceridaemia Pulmonary tuberculosis Ectonucleotide pyrophosphatase/phosphodiesterase 1 deficiency Haemophilia A without inhibitors Follicular lymphoma stage III Mantle cell lymphoma stage III Obesity Lennox-Gastaut syndrome Liposarcoma recurrent Neurodermatitis Angelman's syndrome Medulloblastoma recurrent Canavan disease More trials…

    Learn about Rare Diseases

    Breast angiosarcoma – Treatment Amyotrophic lateral sclerosis Skin angiosarcoma – Life with Disease Lymphangioma Hereditary optic atrophy – Basic Information Hairy cell leukaemia recurrent – Life with Disease Hereditary ataxia – Life with Disease Pleomorphic leiomyosarcoma – Basic Information Pulmonary sarcoidosis Vascular malformation – Diagnostics More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    O15-Water Posenacaftor Dnth103 Tiotropium Cannabidiol Prednisolone Rifamycin Sodium Empasiprubart Gs-5718-03 Tovorafenib 4-IODOPHENYLALANINE I-131 Diclofenac Epolamine Retinol Palmitate Dornase Alfa Anitocabtagene Autoleucel IDOR-1117-2520C Bi 685509 LY3372993 Xenon (129Xe) Naloxegol Oxalate More therapies…

    Learn about Your Condition

    Adenocarcinoma gastric Primary hypogonadism Coagulopathy Urethral valves Alveolar rhabdomyosarcoma Bronchiolitis Anal incontinence Schizoaffective disorder Desmoid tumour Bronchiectasis Hyperparathyroidism primary Metastases to rectum Round cell liposarcoma Breast proliferative changes Thromboembolectomy More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

Male Urogenital Diseases

  • Study on How Abiraterone Affects Oxycodone in Men with Prostate Cancer

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Prostate cancer
    Investigated Drugs:
    • Oxycodone Hydrochloride
    The Netherlands

  • Study on Atorvastatin’s Effect on Prostate Cancer Progression in Patients Undergoing Androgen Deprivation Therapy

    Recruiting

    3 1 1
    Investigated Diseases:
    • Prostate cancer
    • Prostate cancer recurrent
    Investigated Drugs:
    • Atorvastatin
    Denmark Estonia Finland Norway

  • Study on Docetaxel, Cabazitaxel, and Darolutamide for Men with Metastatic Castration-Resistant Prostate Cancer

    Recruiting

    2 1 1 1
    Investigated Diseases:
    • Hormone-refractory prostate cancer
    Investigated Drugs:
    • Cabazitaxel
    • Darolutamide
    • Docetaxel
    The Netherlands

  • Study on Chemo-Immunotherapy with Avelumab for Patients with Locally Advanced Urothelial Cancer

    Recruiting

    2 1 1 1
    Investigated Diseases:
    • Transitional cell carcinoma
    Investigated Drugs:
    • Avelumab
    The Netherlands

  • Feasibility of Sequential Radium Ra-223 Dichloride After Triplet Therapy in High‑Volume Metastatic Hormone‑Sensitive Prostate Cancer Patients (Phase II)

    Not yet recruiting

    2 1 1 1
    Investigated Diseases:
    • Hormone-dependent prostate cancer
    Investigated Drugs:
    • Radium Ra 223 Dichloride
    Spain

  • Phase II Study of Lutetium (177Lu) Zadavotide Guraxetan Radioligand Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer

    Not yet recruiting

    2 1 1
    Investigated Diseases:
    • Hormone-refractory prostate cancer
    Investigated Drugs:
    • Lutetium (177Lu) Zadavotide Guraxetan
    Sweden
Previous Page
1 … 10 11 12 13 14 … 24
Next Page

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!